The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Neonatal Signs After Late In Utero Exposure to Serotonin Reuptake Inhibitors: Literature Review and Implications for Clinical Applications
Abstract
CONTEXT: A neonatal behavioral syndrome linked to in utero serotonin reuptake inhibitor (SRI) exposure during the last trimester of pregnancy has been identified. The US Food and Drug Administration (FDA) and drug manufacturers have recently agreed to a class labeling change for SRIs, which include selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs), to include information about potential adverse events in neonates exposed in utero. Integration of data about the neonatal behavioral syndrome into the management of pregnancy in women who take SRIs is a current challenge for physicians. OBJECTIVES: To review evidence regarding the SRI-related neonatal syndrome and to help clinicians guide their patients in a risk-benefit decision-making process. DATA SOURCES: We searched MEDLINE (1966-February 2005) and PsycINFO (1974-February 2005). All articles related to neonatal signs after in utero SRI exposure were acquired, as well as unpublished data on this topic from the FDA advisory committee meeting of June 2004. References cited in case reports and studies were reviewed. Foreign-language literature was included and translated to English. STUDY SELECTION AND DATA EXTRACTION: Studies were included if they had clearly identified maternal SRI exposure for a minimum of the final trimester of pregnancy through delivery and assessed neonatal outcomes. We identified 13 case reports describing a total of 18 cases. Nine cohort studies met criteria. When not included in the published article, relative risks and 95% confidence intervals (CIs) were computed from raw data and summary risk ratios and 95% CIs were determined with Mantel-Haenszel estimates. DATA SYNTHESIS: Compared with early gestational SRI exposure or no exposure, late SRI exposure carries an overall risk ratio of 3.0 (95% CI, 2.0-4.4) for a neonatal behavioral syndrome. The most SRI-related neonatal case reports involved fluoxetine and paroxetine exposures. Neonates primarily display central nervous system, motor, respiratory, and gastrointestinal signs that are usually mild and disappear by 2 weeks of age. Medical management has consisted primarily of supportive care in special care nurseries. A severe syndrome that consists of seizures, dehydration, excessive weight loss, hyperpyrexia, or intubation is rare in term infants (1/313 quantifiable cases). There have been no reported neonatal deaths attributable to neonatal SRI exposure. CONCLUSIONS: Available evidence indicates that in utero exposure to SRIs during the last trimester through delivery may result in a self-limited neonatal behavioral syndrome that can be managed with supportive care. The risks and benefits of discontinuing an SRI during pregnancy need to be carefully weighed for each individual patient. Development and validation of assessment methods and clinical management strategies are critical to advancing this research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Psychiatric disorders in America: the epidemiologic catchment area study
(1991) · Choice Reviews Online · doi:10.5860/choice.28-5931 · Cited by 2,555
Developmental Pharmacology — Drug Disposition, Action, and Therapy in Infants and Children
Kearns, G. L., Abdel-Rahman, S. M., Alander, S. W., Blowey, D. L., Leeder, J. S., & Kauffman, R. E. (2003) · New England Journal of Medicine · doi:10.1056/nejmra035092 · Cited by 2,421
Kessler, R. (1993) · Journal of Affective Disorders · doi:10.1016/0165-0327(93)90026-g · Cited by 2,207
Early skin-to-skin contact for mothers and their healthy newborn infants
Moore, E. R., Bergman, N., Anderson, G. C., & Medley, N. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003519.pub4 · Cited by 1,736
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.6.705 · Cited by 1,342
Birth Outcomes in Pregnant Women Taking Fluoxetine
Chambers, C. D., Johnson, K. A., Dick, L. M., Felix, R. J., & Jones, K. L. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351402 · Cited by 735
Is there a role for 5-HT1A agonists in the treatment of depression?
Blier, P., & Ward, N. M. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01643-8 · Cited by 529
Field, T. (1995) · Infant Behavior and Development · doi:10.1016/0163-6383(95)90003-9 · Cited by 524
Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.5.592 · Cited by 434
Kulin, N. A., Pastuszak, A., Sage, S. R., Schick-Boschetto, B., Spivey, G., Feldkamp, M., Ormond, K., Matsui, D., Stein-Schechman, A. K., Cook, L., et al. (1998) · JAMA · doi:10.1001/jama.279.8.609 · Cited by 424
Morselli, P. L., Franco-Morselli, R., & Bossi, L. (1980) · Clinical Pharmacokinetics · doi:10.2165/00003088-198005060-00001 · Cited by 387
Sanz, E. J., De-las-Cuevas, C., Kiuru, A., Bate, A., & Edwards, R. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17865-9 · Cited by 382
Placental Passage of Antidepressant Medications
Hendrick, V., Stowe, Z. N., Altshuler, L. L., Hwang, S., Lee, E., & Haynes, D. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.5.993 · Cited by 380
Pregnancy Outcome Following First-Trimester Exposure to Fluoxetine (Prozac)
Pastuszak, A. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03500170076037 · Cited by 368
Laine, K., Heikkinen, T., Ekblad, U., & Kero, P. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.7.720 · Cited by 331
The serotonin syndrome and its treatment
Gillman, P. K. (1999) · Journal of Psychopharmacology · doi:10.1177/026988119901300111 · Cited by 306
Serotonin Reuptake Inhibitor Withdrawal
Coupland, N. J., Bell, C. J., & Potokar, J. P. (1996) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199610000-00003 · Cited by 303
Neonate Characteristics After Maternal Use of Antidepressants in Late Pregnancy
Källén, B. (2004) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/archpedi.158.4.312 · Cited by 300
Delivery outcome after the use of antidepressants in early pregnancy
Ericson, A., Källén, B., & Wiholm, B.-E. (1999) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050664 · Cited by 284
Maternal Selective Serotonin Reuptake Inhibitor Use During Pregnancy and Newborn Neurobehavior
Zeskind, P. S., & Stephens, L. E. (2004) · Pediatrics · doi:10.1542/peds.113.2.368 · Cited by 280
Perinatal Outcome Following Third Trimester Exposure to Paroxetine
Costei, A. M., Kozer, E., Ho, T., Ito, S., & Koren, G. (2002) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/archpedi.156.11.1129 · Cited by 270
Risk-Benefit Decision Making for Treatment of Depression During Pregnancy
Wisner, K. L., Zarin, D. A., Holmboe, E. S., Appelbaum, P. S., Gelenberg, A. J., Leonard, H. L., & Frank, E. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.12.1933 · Cited by 265
Self-citationSelective Serotonin Reuptake Inhibitor-Induced Serotonin Syndrome: Review
Lane, R., & Baldwin, D. (1997) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199706000-00012 · Cited by 247
Oberlander, T. F., Misri, S., Fitzgerald, C. E., Kostaras, X., Rurak, D., & Riggs, W. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0214 · Cited by 244
Einarson, A., Fatoye, B., Sarkar, M., Lavigne, S. V., Brochu, J., Chambers, C., Mastroiacovo, P., Addis, A., Matsui, D., Schuler, L., et al. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.10.1728 · Cited by 240
Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation
Heikkinen, T. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(02)17634-x · Cited by 209
Antidepressant treatment during breast-feeding
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.9.1132 · Cited by 200
The Use of Psychotropic Medications During Breast-Feeding
Burt, V. K., Suri, R., Altshuler, L., Stowe, Z., Hendrick, V. C., & Muntean, E. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.7.1001 · Cited by 194
(2018) · Pediatric Clinical Practice Guidelines & Policies · doi:10.1542/9781610021494-part05-neonatal_drug_withdr · Cited by 185
Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors
Nordeng, H., Lindemann, R., Perminov, K. V., & Reikvam1, Å. (2001) · Acta Paediatrica · doi:10.1080/080352501300067596 · Cited by 181
The serotonin syndrome scale: first results on validity
Hegerl, U., Bottlender, R., Gallinat, J., Kuss, H.-J., Ackenheil, M., & Möller, H.-J. (1998) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s004060050024 · Cited by 180
Extrapyramidal side effects and increased serum prolactin following fluoxetine, a new antidepressant
Meltzer, H. Y., Young, M., Metz, J., Fang, V. S., Schyve, P. M., & Arora, R. C. (1979) · Journal of Neural Transmission · doi:10.1007/bf01250091 · Cited by 167
Antidepressant discontinuation syndromes
Haddad, P. M., Anderson, I., & Rosenbaum, J. (2004) · Adverse Syndromes and Psychiatric Drugs · doi:10.1093/med/9780198527480.003.0010 · Cited by 160
Early Skin‐To‐Skin Contact for Mothers and Their Healthy Newborn Infants
Anderson, G. C., Moore, E. R., Hepworth, J. T., & Bergman, N. (2003) · Birth · doi:10.1046/j.1523-536x.2003.00247.x · Cited by 156
Birth outcomes following prenatal exposure to fluoxetine
Cohen, L. S., Heller, V. L., Bailey, J. W., Grush, L. R., Ablon, J. S., & Bouffard, S. M. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00877-5 · Cited by 137
Prolonged Prenatal Psychotropic Medication Exposure Alters Neonatal Acute Pain Response
Oberlander, T. F., GRUNAU, R. E., Fitzgerald, C., Ellwood, A.-L., Misri, S. K., Rurak, D. W., & Riggs, K. W. (2002) · Pediatric Research · doi:10.1203/00006450-200204000-00008 · Cited by 134
Fluoxetine Hydrochloride (Prozac) Toxicity in a Neonate
SPENCER, M. J. (1993) · PEDIATRICS · doi:10.1542/peds.92.5.721 · Cited by 121
Effects of Third Trimester Fluoxetine Exposure on the Newborn
GOLDSTEIN, D. J. (1995) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199512000-00005 · Cited by 114
Neonatal paroxetine withdrawal syndrome
Stiskal, J. A., Kulin, N., Koren, G., Ho, T., & Ito, S. (2001) · Archives of Disease in Childhood Fetal & Neonatal · doi:10.1136/fn.84.2.f134 · Cited by 110
Citalopram and breast-feeding: serum concentration and side effects in the infant
Schmidt, K., Olesen, O. V., & Jensen, P. N. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00155-9 · Cited by 106
Current knowledge of Kangaroo Mother Intervention
Charpak, N., Ruíz, J. G., & de Calume, Z. F. (1996) · Current Opinion in Pediatrics · doi:10.1097/00008480-199604000-00004 · Cited by 91
A Review of Developmental Aspects of Cytochrome P450
Oesterheld, J. R. (1998) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.1998.8.161 · Cited by 80
Possible Biological Mechanisms of the Serotonin Reuptake Inhibitor Discontinuation Syndrome
Schatzberg, A. F., Haddad, P. M., Kaplan, E. M., Lejoyeux, M., Rosenbaum, J. F., Young, A. H., & Zajecka, J. (1997) · The Journal of Clinical Psychiatry · Cited by 69
Relation between Prenatal Maternal Mood and Anxiety and Neonatal Health
Misri, S. K., Oberlander, T. F., Fairbrother, N., Carter, D., Ryan, D. M., Kuan, A. J., & Reebye, P. N. (2004) · The Canadian Journal of Psychiatry · doi:10.1177/070674370404901006 · Cited by 68
Paroxetine withdrawal syndrome in a neonate
Dahl, M. L., Olhager, E., & Ahlner, J. (1997) · The British Journal of Psychiatry · doi:10.1192/bjp.171.4.391c · Cited by 67
Suspected congenital sertraline dependence
Kent, L., & Laidlaw, J. (1995) · The British Journal of Psychiatry · doi:10.1192/bjp.167.3.412b · Cited by 64
Potential Fluoxetine Chloride (Prozac) Toxicity in a Newborn
Mhanna, M. J., Bennet, J., & Izatt, S. D. (1997) · PEDIATRICS · doi:10.1542/peds.100.1.158 · Cited by 60
Fluoxetine Toxicity in a Breastfed Infant
Hale, T. W., Shum, S., & Grossberg, M. (2001) · Clinical Pediatrics · doi:10.1177/000992280104001207 · Cited by 60
Clozapine withdrawal effects and receptor profiles of typical and atypical neuroleptics
Verghese, C., de León, J., Nair, C., & Simpson, G. M. (1996) · Biological Psychiatry · doi:10.1016/0006-3223(95)00215-4 · Cited by 60
Psychopharmacologic Agents and Electroconvulsive Therapy during Pregnancy and the Puerperium
Wisner, K. L., & Perel, J. M. (1988) · Springer eBooks · doi:10.1007/978-1-4684-5439-0_12 · Cited by 42
Self-citationNTP‐CERHR Expert Panel Report on the reproductive and developmental toxicity of fluoxetine
Hines, R. N., Adams, J., Louis, G. M. B., Faber, W. D., Holson, J. F., Jacobson, S. W., Keszler, M., McMartin, K. E., Segraves, R. T., Singer, L. T., et al. (2004) · Birth Defects Research Part B Developmental and Reproductive Toxicology · doi:10.1002/bdrb.20014 · Cited by 35
[Withdrawal symptoms in a neonate following exposure to venlafaxine during pregnancy].
Bloem, B. R., Roofthooft, D. W. E., Lammers, G. J., de Beaufort, A., & Of, B. (2003) · PubMed · Cited by 30
Withdrawal reactions of a premature neonate after maternal use of paroxetine
Nijhuis, I. J. M., Rooij, G. W. K.-V., & Bosschaart, A. N. (2001) · Archives of Disease in Childhood Fetal & Neonatal · doi:10.1136/fn.84.1.f77a · Cited by 26
Fluoxetine Toxicity in a Preterm Infant
Mohan, C. G., & Moore, J. J. (2000) · Journal of Perinatology · doi:10.1038/sj.jp.7200388 · Cited by 24
Onthoudingsverschijnselen bij een neonatus na blootstelling aan venlafaxine tijdens de zwangerschap
Moor, R., Mourad, L. M., ter Haar, J., & Egberts, T. C. G. (2003) · Utrecht University Repository (Utrecht University) · Cited by 23
Paroxetin-Entzugs-Syndrom als Differenzialdiagnose der akuten neonatalen Enzephalopathie?
Herbst, F., & Gortner, L. (2003) · Zeitschrift für Geburtshilfe und Neonatologie · doi:10.1055/s-2003-45176 · Cited by 15
Cited by
Oberlander, T. F., Weinberg, J., Papsdorf, M., Grunau, R., Misri, S., & Devlin, A. M. (2008) · Epigenetics · doi:10.4161/epi.3.2.6034 · Cited by 1,432
Practice Bulletin No. 183: postpartum hemorrhage
(2017) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000002351 · Cited by 1,406
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
“neonatal adaptation syndrome (PNAS) [1121-1123], while”
Cohen, L. S. (2006) · JAMA · doi:10.1001/jama.295.5.499 · Cited by 1,031
Practice Guideline for the Treatment of Patients With Obsessive-Compulsive Disorder
(2008) · APA Practice Guidelines for the Treatment of Psychiatric Disorders: Comprehensive Guidelines and Guideline Watches · doi:10.1176/appi.books.9780890423363.149114 · Cited by 1,028
Metadata
- Authors
- Moses-Kolko, E. L., Bogen, D., Perel, J., Bregar, A., Uhl, K., Levin, B., & Wisner, K. L.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2005-05-18
- Volume
- 293
- Issue
- 19
- Pages
- 2372
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2027277232
- Cited by
- 533
- References
- 56
- FWCI
- 36.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.